Barcelona Science Park announces a new artistic intervention contest to decorate an outdoor space Blog Post

Barcelona Science Park (PCB) announces a new artistic intervention contest to promote the interaction between art and science. The public and anonymous event offers the opportunity to create, with total thematic freedom, a mural in an outdoor space of 4.5 metres of height per 6.5 metres of width in the Clúster II building, in a junction of various areas of the park at different levels.

 

Esteve adds its weight to the fight against the pandemic through donations and research collaborations Blog Post

Esteve is participating in 3 European projects aimed at identifying and/or repositioning drugs that are active against COVID-19; at detecting SARS-CoV-2 ; and at analyzing the involvement of the sigma-1 receptor in the viral infection cycle. Additionally, the pharmaceutical group –which has its Drug Discovery and Preclinical Development Center at the Barcelona Science Park– has made donations targeted at health professionals, patients and people on the frontline of the COVID-19 pandemic.

 

Chemotargets opens an investment round to enter a new phase of growth Blog Post

Chemotargets, a global leader in predictive analytics solutions for the pharma and biotech sector, begins a phase of transformation to expand its activity in the drug discovery sector as a biotechnology company. The company, based in the Barcelona Science Park, is opening an investment round to undertake the transformation of its business model, with tadvice and support of GENESIS Biomed, also located in the Park, and CREA Inversión. 

 

The Park collaborates on a project for mass COVID-19 testing service led by IBEC, IRB Barcelona and CNAG-CRG Blog Post

The Government of Catalonia has approved the creation of the Orfeu Programme with the aim of having new diagnostic tests for COVID-19, as a complement to the capacity of the health system. In an initial phase, there will be two mass testing sites: one at the Barcelona Science Park, jointly coordinated by the Institute for Bioengineering of Catalonia (IBEC), the Institute for Research in Biomedicine (IRB Barcelona) and the Centro Nacional de Análisis Genómico (CNAG-CRG); and another coordinated by the Centre for Genomic Regulation (CRG) at its labs at the Barcelona Biomedical Research Park (PRBB).

 

Nostrum Biodiscovery appoints Ezequiel Mas as its new CEO and embarks on an ambitious expansion plan Blog Post

Nostrum Biodiscovery (NBD) has appointed Ezequiel Mas del Molino as its new CEO to lead a new phase of the company, which is establishing a leading position in the European market as a provider of cutting-edge bioinformatics technologies for drug design and discovery. NBD –a spin-off from the Institute for Research in Biomedicine (IRB Barcelona), the Barcelona Supercomputing Centre (BSC-CNS), the University of Barcelona (UB) and the Catalan Institution for Research and Advanced Studies (ICREA)– is located at the Barcelona Science Park and the North Campus of the Universitat Politècnica de Catalunya (UPC).

 

IRB Barcelona collaborates with Amazon to develop a computational tool speeding up research against SARS-CoV-2 Blog Post

IRB Barcelona’s Structural Bioinformatics and Network Biology Laboratory, led by ICREA researcher Patrick Aloy at the Barcelona Science Park, has joined forces with Amazon Sciences to develop a computational tool, using artificial intelligence, that generates a open access database that includes all the published scientific results related to the treatment of SARS-CoV-2.